← Back to Clinical Trials
Recruiting NCT04763317

NCT04763317 Precision Medicine in the Prostate Cancer Care Pathway

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04763317
Status Recruiting
Phase
Sponsor Institute of Cancer Research, United Kingdom
Condition Prostate Cancer
Study Type OBSERVATIONAL
Enrollment 3,000 participants
Start Date 2019-02-14
Primary Completion 2029-12-31

Eligibility & Interventions

Sex Male only
Min Age 30 Years
Max Age 70 Years
Study Type OBSERVATIONAL
Interventions
Prostate cancer risk gene panel

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 3,000 participants in total. It began in 2019-02-14 with a primary completion date of 2029-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to evaluate the use of a prostate cancer specific predisposition genetic panel test in men with / at high risk of prostate cancer. The genetic test will analyse men's DNA samples for the presence of mutations in rare genes as well as common genetic variation to provide men with information about their risk of prostate cancer. This study will evaluate the clinical impact of the test on risk assessment and clinical management in terms of screening and treatment.

Eligibility Criteria

Inclusion Criteria: Affected cohort: 1. Affected with PrCa \< 60 years or 2. Affected with metastatic castration resistant PrCa (mCRPC) at any age or Aggressive PrCa Gleason 4+4 or higher \<70 years 3. Affected with family history defined as three or more cases any age (FDR or SDR) Unaffected cohort: (This cohort is no longer recruiting, it has completed recruitment) Aged \>30 and with a family history defined as: 1. FDR diagnosed \< 70 2. 2 or more cases in First or Second Degree Relatives (FDR/SDR) with one case diagnosed \< 70 years 3. 3 or more cases at any age (on same side of family) Exclusion Criteria: * • WHO performance status 4

Frequently Asked Questions

Who can join the NCT04763317 clinical trial?

This trial is open to male participants only, aged 30 Years or older, up to 70 Years, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04763317 currently recruiting?

Yes, NCT04763317 is actively recruiting participants. Visit ClinicalTrials.gov or contact Institute of Cancer Research, United Kingdom to inquire about joining.

Where is the NCT04763317 trial being conducted?

This trial is being conducted at Sutton, United Kingdom.

Who is sponsoring the NCT04763317 clinical trial?

NCT04763317 is sponsored by Institute of Cancer Research, United Kingdom. The trial plans to enroll 3,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology